Dena Abdulbadea Nuwaylati

Dr. Dena Abdulbadea Nuwaylati

Department of Clinical Biochemistry, Faculty of Medicine, Jeddah University, Jeddah, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
ABAbdulhadi Bima
Abdulhadi Bima
Basmah Medhat EldakhakhnyBasmah Medhat Eldakhakhny
Basmah Medhat Eldakhakhny
Dena Abdulbadea NuwaylatiDena Abdulbadea Nuwaylati
Dena Abdulbadea Nuwaylati
AAABRAR MUHAMMED ALNAMI
ABRAR MUHAMMED ALNAMI
MAMohammed ali Ajabnoor
Mohammed ali Ajabnoor
AEAyman Zaky Elsamanoudy
Ayman Zaky Elsamanoudy
This scoping review aims to clarify the interplay between obesity, vitamin D deficiency, cellular senescence, and obesity-related metabolic consequences, mainly subclinical atherosclerosis, and non-alcoholic fatty liver disease (NAFLD). Obesity is a significant global health problem that involves cellular, environmental, behavioral, and genetic elements. The fundamental cause of obesity throughout all life stages is an energy imbalance, and its consequences are countless and, foremost, very common. Obesity has been comprehensively studied in the literature given its association with low serum vitamin D, with many proposed mechanisms linking the two conditions. Moreover, markers of exaggerated cellular senescence have been proven to accumulate in obese individuals. Subclinical atherosclerosis initiates an early stage that ends in serious cardiac events, and obesity, low vitamin D, and senescent cells largely contribute to its associated chronic low-grade inflammation. Furthermore, NAFLD signifies the hepatic manifestation of metabolic syndrome, and studies have highlighted the important role of obesity, vitamin D deficiency, and cellular senescence in its development. Therefore, we outlined the most important mechanisms tying these conditions to one another.

5 March 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Dena Abdulbadea NuwaylatiDena Abdulbadea Nuwaylati
Dena Abdulbadea Nuwaylati
ZAZuhier A. Awan
Zuhier A. Awan
Low-density lipoprotein cholesterol (LDL-C) is typically estimated by the Friedewald equation to guide atherosclerotic cardiovascular disease (ASCVD) management despite its flaws. Martin–Hopkins and Sampson-NIH equations were shown to outperform Friedewald’s in various populations. Our aim was to derive a novel equation for accurate LDL-C estimation in Saudi Arabians and to compare it to Friedewald, Martin–Hopkins and Sampson-NIH equations. This is a cross-sectional study on 2245 subjects who were allocated to 2 cohorts; a derivation (1) and a validation cohort (2). Cohort 1 was analyzed in a multiple regression model to derive an equation (equationD) for estimating LDL-C. The agreement between the measured (LDL-CDM) and calculated levels was tested by Bland–Altman analysis, and the biases by absolute error values. Validation of the derived equation was carried out across LDL-C and triglyceride (TG)-stratified groups. The mean LDL-CDM was 3.10 ± 1.07 and 3.09 ± 1.06 mmol/L in cohorts 1 and 2, respectively. The derived equation is: LDL-CD = 0.224 + (TC × 0.919) – (HDL-C × 0.904) – (TG × 0.236) – (age × 0.001) – 0.024. In cohort 2, the mean LDL-C (mmol/L) was estimated as 3.09 ± 1.06 by equationD, 2.85 ± 1.12 by Friedewald, 2.95 ± 1.09 by Martin–Hopkins, and 2.93 ± 1.11 by Sampson-NIH equations; statistically significant differences between direct and calculated LDL-C was observed with the later three equations (P < 0.001). Bland–Altman analysis showed the lowest bias (0.001 mmol/L) with equationD as compared to 0.24, 0.15, and 0.17 mmol/L with Friedewald, Martin–Hopkins, and Sampson-NIH equations, respectively. The absolute errors in all guideline-stratified LDL-C categories was the lowest with equationD, which also showed the best classifier of LDL-C according to guidelines. Moreover, equationD predicted LDL-C levels with the lowest error with TG levels up to 5.63 mmol/L. EquationD topped the other equations in estimating LDL-C in Saudi Arabians as it could permit better estimation when LDL-C is < 2.4 mmol/L, in familial hyperlipidemia, and in hypertriglyceridemia, which improves cardiovascular outcomes in high-risk patients. We recommend further research to validate equationD in a larger dataset and in other populations.

31 December 2024 in Precision and Future Medicine
Verified
Journal Article
Open access
PDF file
Dena Abdulbadea NuwaylatiDena Abdulbadea Nuwaylati
Dena Abdulbadea Nuwaylati
HDHussam Daghistani
Hussam Daghistani
NSNoor Ahamd Shaik
Noor Ahamd Shaik
ZAZuhair Ahmed Awan
Zuhair Ahmed Awan
Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder characterized by severe hypertriglyceridemia and recurrent pancreatitis, often manifesting in childhood. The condition results from variants in the lipoprotein lipase (LPL<) gene, which lead to impaired fat metabolism. We report the case of an 18-year-old Saudi male with a lifelong history of hypertriglyceridemia and recurrent episodes of pancreatitis. Laboratory investigations revealed severe hypertriglyceridemia and low high-density lipoprotein cholesterol, consistent with FCS. A comprehensive evaluation excluded secondary causes of hyperlipidemia, suggesting a potential genetic basis for the condition. Whole-exome sequencing identified a novel homozygous missense variant (c.1307G> A; p.Gly436Glu) in the LPL< gene. Bioinformatics analysis predicted this variant to be deleterious, potentially disrupting the structure and stability of the LPL enzyme and impairing its ability to hydrolyze dietary fats. This finding suggested a causal link between the variant and the patient’s FCS phenotype. This case highlights the importance of molecular diagnosis in FCS, enabling the identification of causative genetic alterations and improving our understanding of the link between LPL dysfunction and severe metabolic disorders.

16 August 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
FMFatma Mokhtar
Fatma Mokhtar
Dena Abdulbadea NuwaylatiDena Abdulbadea Nuwaylati
Dena Abdulbadea Nuwaylati
Jogchum PlatJogchum Plat
Jogchum Plat
Susan L. M. CoortSusan L. M. Coort
Susan L. M. Coort
HPHerman Popeijus
Herman Popeijus
Ronald P. MensinkRonald P. Mensink
Ronald P. Mensink
Background: Interindividual variability in intestinal cholesterol absorption contributes to differences in serum lipid concentrations and cardiovascular risk. Total cholesterol (TC)-standardized campesterol and sitosterol levels are established markers of cholesterol absorption. However, genetic variants in Europeans associated with these markers remain incompletely characterized. Methods: A genome-wide association study (GWAS) was performed in 398 healthy individuals of European ancestry. Samples were genotyped using the Precision Medicine Research Array (PMRA). After quality control, 166,037 common genetic variants with a minor allele frequency (MAF) > 20% were analyzed. Associations between genetic variants and intestinal cholesterol absorption markers (campesterol/TC and sitosterol/TC) were evaluated using additive and recessive genetic models. Results: A total of 16 SNPs were identified. Eight SNPs overlapped with both campesterol/TC and sitosterol/TC, of which 2 reached genome-wide significance. Six overlapping SNPs were associated with higher concentrations of both markers: 3 SNPs in ABCG8 (rs4299376, rs6544713, and rs4245791), 1 SNP in ADAM12 (rs4962526), and 2 SNPs in non-coding regions (rs260769 and rs5011112). Additionally, two SNPs (rs2033254 and rs12708980) in CETP were associated with lower concentrations of these markers. Five of the identified SNPs have not previously been linked to markers of intestinal cholesterol absorption. Conclusions: This GWAS confirmed previously reported associations within ABCG8 and identified candidate loci in CETP and ADAM12 that may be involved in intestinal cholesterol absorption. These findings contribute to our understanding of genetic factors underlying intestinal cholesterol absorption and highlight candidate loci for future replication and functional studies.

29 June 2026 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
Dena Abdulbadea NuwaylatiDena Abdulbadea Nuwaylati
Dena Abdulbadea Nuwaylati
Ronald P. MensinkRonald P. Mensink
Ronald P. Mensink
Peter J. JorisPeter J. Joris
Peter J. Joris
Susan L. M. CoortSusan L. M. Coort
Susan L. M. Coort
Jogchum PlatJogchum Plat
Jogchum Plat
The genetic background of hypertriglyceridemia is complex. In this systematic review and meta-analysis, we determined genetic variants associated with fasting triglyceride (TG) and very-low-density lipoprotein-TG (VLDL-TG) concentrations in European adults. We searched PubMed and the National Human Genome Research Institute-European Bioinformatics Institute (NHGRI-EBI) genome-wide association studies catalog for studies on genetic variants associated with fasting TG and VLDL-TG concentrations. We performed the meta-analysis on 23 variants from studies that met our criteria. A fixed-effects model was applied, with a random-effects model used when significant heterogeneity was detected. The Ensembl Variant Effect Predictor was used to annotate these variants. Overall, 157 studies were included, of which 130 were used for meta-analysis. Overall, 1837 variants were related to fasting TG and/or VLDL-TG (P ≤ .05). Our meta-analysis revealed 11 genetic variants associated with fasting TG: rs58542926 in the transmembrane 6 superfamily member 2 (TM6SF2) gene, rs738409 in the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene, rs7903146 in the transcription factor 7-like 2 (TCF7L2) gene, rs320 and rs328 in the lipoprotein lipase (LPL) gene, and rs1801282 in the peroxisome proliferator-activated receptor γ2 (PPARγ2) gene were associated with lower TG concentrations, while rs693 in the apolipoprotein-B (APOB) gene, rs5128 in the apolipoprotein-c3 (APOC3) gene, rs662799 in the apolipoprotein A-V (APOA5) gene, rs662 in the paraoxonase 1 (PON1) gene, and rs1800588 in the hepatic lipase C (LIPC) gene were associated with higher TG concentrations. Five of those (rs58542926, rs738409, rs320, rs328, and rs1801282) were predicted to be deleterious to the protein function. This study identified variants associated with fasting TG and/or VLDL-TG concentrations in European adults, which may help in identifying genetically susceptible individuals and strengthening the accuracy of genetic risk prediction for TG-related outcomes.